Nouvelles Eulerpool Travere Therapeutics

Eulerpool-AFX Travere Therapeutics

Travere Therapeutics Actualités des actions

Travere Therapeutics est surveillé par de nombreux journalistes et investisseurs du monde entier. Nous regroupons ici les dernières actualités Travere Therapeutics.

• 12 septembre ·

  Yahoo
  Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 12 septembre ·

  Thefly.com
  Travere Therapeutics price target raised by $3 at JPMorgan, here's why
• 10 septembre ·

  Yahoo
  Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
• 10 septembre ·

  Thefly.com
  Travere Therapeutics price target raised by $5 at Canaccord, here's why
• 6 septembre ·

  Thefly.com
  Travere Therapeutics price target raised by $1 at BofA, here's why
• 6 septembre ·

  Seeking Alpha
  Travere gains on full FDA approval for kidney drug Filspari
• 5 septembre ·

  Yahoo
  Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
• 5 septembre ·

  GlobeNewswire
  Travere Therapeutics Announces Full FDA Approval of FILSPARI? (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
• 5 septembre ·

  Thefly.com
  Travere Therapeutics' Filspari in kidney function granted full approval by FDA
• 4 septembre ·

  Yahoo
  High Growth Tech Stocks To Watch In September 2024